Leomanni Ludovica, Collatuzzo Giulia, Sansone Emanuele, Sala Emma, De Palma Giuseppe, Porru Stefano, Spiteri Gianluca, Monaco Maria Grazia Lourdes, Basso Daniela, Pavanello Sofia, Scapellato Maria Luisa, Larese Filon Francesca, Cegolon Luca, Mauro Marcella, Lodi Vittorio, Lazzarotto Tiziana, Noreña Ivan, Reinkemeyer Christina, Giang Le Thi Thu, Fabiánová Eleonóra, Strhársky Jozef, Dell'Omo Marco, Murgia Nicola, Carrasco-Ribelles Lucía A, Violán Concepción, Mates Dana, Rascu Agripina, Vimercati Luigi, De Maria Luigi, Asafo Shuffield S, Ditano Giorgia, Abedini Mahsa, Boffetta Paolo
Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25121 Brescia, Italy.
Vaccines (Basel). 2023 Sep 26;11(10):1527. doi: 10.3390/vaccines11101527.
The effectiveness of the immunity provided by SARS-CoV-2 vaccines is an important public health issue. We analyzed the determinants of 12-month serology in a multicenter European cohort of vaccinated healthcare workers (HCW).
We analyzed the sociodemographic characteristics and levels of anti-SARS-CoV-2 spike antibodies (IgG) in a cohort of 16,101 vaccinated HCW from eleven centers in Germany, Italy, Romania, Slovakia and Spain. Considering the skewness of the distribution, the serological levels were transformed using log or cubic standardization and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log or cubic antibody level and the corresponding 95% confidence interval (CI) for different factors and combined them in random-effects meta-analyses.
We included 16,101 HCW in the analysis. A high antibody level was positively associated with age (RR = 1.04, 95% CI = 1.00-1.08 per 10-year increase), previous infection (RR = 1.78, 95% CI 1.29-2.45) and use of Spikevax [Moderna] with combinations compared to Comirnaty [BioNTech/Pfizer] (RR = 1.07, 95% CI 0.97-1.19) and was negatively associated with the time since last vaccine (RR = 0.94, 95% CI 0.91-0.98 per 30-day increase).
These results provide insight about vaccine-induced immunity to SARS-CoV-2, an analysis of its determinants and quantification of the antibody decay trend with time since vaccination.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗所提供免疫力的有效性是一个重要的公共卫生问题。我们分析了欧洲一个多中心接种疫苗医护人员队列中12个月血清学的决定因素。
我们分析了来自德国、意大利、罗马尼亚、斯洛伐克和西班牙11个中心的16101名接种疫苗医护人员队列的社会人口学特征和抗SARS-CoV-2刺突抗体（IgG）水平。考虑到分布的偏态性，血清学水平采用对数或立方标准化进行转换，并通过除以中心特异性标准误进行标准化。我们拟合了中心特异性多变量回归模型，以估计对数或立方抗体水平增加一个标准差时队列特异性相对风险（RR）以及不同因素对应的95%置信区间（CI），并将它们纳入随机效应荟萃分析。
我们纳入了16101名医护人员进行分析。高抗体水平与年龄呈正相关（RR = 1.04，每增加10岁，95%CI = 1.00 - 1.08）、既往感染（RR = 1.78，95%CI 1.29 - 2.45）以及与使用Spikevax[Moderna]联合疫苗相比使用Comirnaty[BioNTech/辉瑞]（RR = 1.07，95%CI 0.97 - 1.19）呈正相关，与上次接种疫苗后的时间呈负相关（每增加30天，RR = 0.94，95%CI 0.91 - 0.98）。
这些结果提供了关于疫苗诱导的针对SARS-CoV-2免疫力的见解，对其决定因素的分析以及接种疫苗后抗体随时间衰减趋势的量化。
